Gemeinsame Stellungnahme zur neuen Empfehlung der WHO zur Behandlung der multiresistenten und Rifampicin-resistenten Tuberkulose^[*]

• Literatur

• 1 WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019 Licence: CC BY-NC-SA 3.0 IGO
• 2 Schaberg T, Bauer T, Brinkmann F. et al. S2k-Leitlinie: Tuberkulose im Erwachsenenalter. Pneumologie [Internet] 2017; 71: 325-397 Available from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-105954
• 3 Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment – 2017. Ahmad N, Ahuja SD. et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet [Internet] 2018; 392: 821-834 Available from: http://www.ncbi.nlm.nih.gov/pubmed/30215381
• 4 Diacon AH, Pym A, Grobusch MP. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med [Internet] 2014; 371: 723-732 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25140958
• 5 Zhang X, Falagas ME, Vardakas KZ. et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis [Internet] 2015; 7: 603-615 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25973226
• 6 Weiss T, Schönfeld N, Otto-Knapp R. et al. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. Eur Respir J [Internet] 2015; 45: 285-287 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25552739
• 7 World Health Organisation. Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB. Geneva, Switzerland: 2018
• 8 Bloemberg GV, Keller PM, Stucki D. et al. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. N Engl J Med [Internet] 2015; 373: 1986-1988 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26559594
• 9 Polsfuss S, Hofmann-Thiel S, Merker M. et al. Emergence of low level delamanid and bedaquiline resistance during extremely drug resistant tuberculosis treatment. Clin Infect Dis [Internet]. 2019 Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciz074/5305974